Mitsubishi Tanabe Unit Plans 40% Growth In Generics Portfolio In 10 Years
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma Group's generics subsidiary plans a 40% increase in its portfolio within the next 10 years to take advantage of what is expected to be an expanded market for the drugs.
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.